Vial Announces Dosing of First Patient in Phase 1 Healthy Volunteer Trial
Vial Logo
Back to Resources
  • Videos

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

More Resources

Vial Initiates Phase 1 Trial of VIAL-INHBE, an INHBE (Activin E) siRNA for the Treatment of Obesity

Read Article

Dr. Arya M. Sharma, MD, DSc (hon), FRCPC, FCAHS, Emeritus Professor of Medicine at the University of Alberta, highlights INHBE as a promising new target for obesity, acting on both adipocytes and hepatocytes to drive fat-selective weight loss.

Could the next generation of obesity treatments help preserve muscle and enhance fat loss? Dr. Tim Garvey (UAB) shares how INHBE inhibition could complement GLP-1 therapies for broader benefit.

Connect with us.

Interested in receiving a proposal from Vial? Leave us a message and some of your contact info and we’ll be in touch with you shortly.

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy

Contact Us

This field is for validation purposes and should be left unchanged.
Name(Required)
By submitting, you are agreeing to our terms and privacy policy